Antitrust NewsWatch: Johnson & Johnson suit claims Amgen sales tactic threatens Procrit, coerces clinics | Yahoo! Finance

Thursday, October 13, 2005

Johnson & Johnson suit claims Amgen sales tactic threatens Procrit, coerces clinics | Yahoo! Finance

"NEWARK, N.J. (AP) - In a bid to protect its best-selling drug, Procrit, a Johnson & Johnson company has charged Amgen Inc. with antitrust violations, claiming that illegal sales practices force cancer doctors to choose its competing anti-anemia drug. 'The result will be less competition, less physician and patient choice and an increased expense to the public health system,' J&J's Ortho Biotech Products LP charged in a lawsuit."
Johnson & Johnson Seeks to Protect Procrit: Financial News - Yahoo! Finance